Total Payments
$2,693
2024 Payments
$352.43
Companies
17
Transactions
83
Medicare Patients
6,294
Medicare Billing
$1.7M
Payment Breakdown by Category
Food & Beverage$2,600 (96.5%)
Education$92.99 (3.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,600 | 82 | 96.5% |
| Education | $92.99 | 1 | 3.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $624.78 | 16 | $0 (2021) |
| Regeneron Healthcare Solutions, Inc. | $447.35 | 14 | $0 (2024) |
| EyePoint Pharmaceuticals US, Inc. | $268.39 | 4 | $0 (2022) |
| Genentech USA, Inc. | $259.49 | 8 | $0 (2024) |
| ABBVIE INC. | $222.83 | 7 | $0 (2024) |
| Alimera Sciences, Inc. | $209.86 | 12 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $147.10 | 5 | $0 (2021) |
| Mallinckrodt Hospital Products Inc. | $127.07 | 2 | $0 (2021) |
| Astellas Pharma US Inc | $98.70 | 4 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $84.21 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $352.43 | 14 | ABBVIE INC. ($134.11) |
| 2023 | $450.63 | 18 | Regeneron Healthcare Solutions, Inc. ($89.06) |
| 2022 | $394.23 | 13 | Genentech USA, Inc. ($163.60) |
| 2021 | $442.78 | 11 | EyePoint Pharmaceuticals US, Inc. ($172.74) |
| 2020 | $40.38 | 2 | EyePoint Pharmaceuticals US, Inc. ($23.49) |
| 2019 | $552.06 | 12 | Allergan Inc. ($346.11) |
| 2018 | $274.47 | 10 | Allergan Inc. ($142.94) |
| 2017 | $185.62 | 3 | Allergan Inc. ($101.41) |
All Payment Transactions
83 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $32.91 | General |
| Category: EYE CARE | ||||||
| 11/26/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $32.30 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/13/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $18.27 | General |
| Category: Ophthalmology | ||||||
| 10/15/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $24.39 | General |
| Category: Immunology and Ophthalmology | ||||||
| 09/17/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $24.84 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 07/03/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $34.24 | General |
| Category: EYE CARE | ||||||
| 06/05/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $34.24 | General |
| Category: EYE CARE | ||||||
| 04/23/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $32.72 | General |
| Category: EYE CARE | ||||||
| 04/09/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $14.34 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 03/26/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $27.24 | General |
| Category: Ophthalmology | ||||||
| 03/05/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $19.20 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 02/06/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $15.83 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 01/04/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $21.91 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 01/02/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 12/06/2023 | Alimera Sciences, Inc. | ILUVIEN (Drug) | Food and Beverage | Cash or cash equivalent | $14.65 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/27/2023 | AbbVie Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $34.77 | General |
| Category: EYE CARE | ||||||
| 11/13/2023 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $23.43 | General |
| 10/10/2023 | Harrow Eye, LLC | IHEEZO (Drug) | Food and Beverage | In-kind items and services | $20.30 | General |
| Category: OPTOMETRY | ||||||
| 09/27/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $20.26 | General |
| Category: Immunology and Ophthalmology | ||||||
| 09/19/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $31.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 09/01/2023 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $29.76 | General |
| 08/22/2023 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $28.41 | General |
| 08/01/2023 | Alimera Sciences, Inc. | YUTIQ (Drug) | Food and Beverage | Cash or cash equivalent | $16.19 | General |
| Category: OPHTHALMOLOGY | ||||||
| 07/25/2023 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $32.22 | General |
| Category: OPHTHALMOLOGY | ||||||
| 05/23/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $20.24 | General |
| Category: Immunology and Ophthalmology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 1,412 | 3,887 | $1.7M | $468,305 |
| 2022 | 13 | 1,590 | 3,991 | $1.8M | $495,344 |
| 2021 | 11 | 1,508 | 3,461 | $1.5M | $422,500 |
| 2020 | 12 | 1,784 | 3,321 | $1.2M | $334,382 |
Total Patients
6,294
Total Services
14,660
Medicare Billing
$1.7M
Procedure Codes
48
All Medicare Procedures & Services
48 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 48 | 406 | $1.0M | $281,384 | 28.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 308 | 840 | $210,000 | $74,059 | 35.3% |
| 67028 | Injection of drug into eye | Office | 2023 | 110 | 427 | $130,520 | $37,205 | 28.5% |
| 92134 | Imaging of retina | Office | 2023 | 354 | 962 | $101,010 | $27,380 | 27.1% |
| 92250 | Photography of the retina | Office | 2023 | 296 | 769 | $109,967 | $20,226 | 18.4% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 59 | 179 | $109,190 | $9,831 | 9.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 74 | 74 | $30,932 | $8,904 | 28.8% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 46 | 51 | $10,965 | $4,947 | 45.1% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 61 | 93 | $13,485 | $1,645 | 12.2% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 11 | 23 | $7,268 | $1,435 | 19.7% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 15 | 27 | $5,076 | $917.81 | 18.1% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2023 | 30 | 36 | $5,220 | $370.57 | 7.1% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 51 | 420 | $1.0M | $302,447 | 29.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 260 | 582 | $145,500 | $57,693 | 39.7% |
| 67028 | Injection of drug into eye | Office | 2022 | 113 | 445 | $138,840 | $39,985 | 28.8% |
| 92134 | Imaging of retina | Office | 2022 | 362 | 993 | $104,265 | $29,112 | 27.9% |
| 92250 | Photography of the retina | Office | 2022 | 307 | 744 | $106,392 | $19,774 | 18.6% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 185 | 283 | $89,428 | $18,555 | 20.7% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2022 | 65 | 227 | $138,470 | $11,991 | 8.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 50 | 50 | $20,900 | $6,052 | 29.0% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2022 | 48 | 51 | $10,965 | $4,594 | 41.9% |
| 92004 | New patient complete exam of visual system | Office | 2022 | 32 | 32 | $12,128 | $2,562 | 21.1% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2022 | 68 | 92 | $13,340 | $1,061 | 8.0% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2022 | 38 | 56 | $8,120 | $1,050 | 12.9% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2022 | 11 | 16 | $3,008 | $467.63 | 15.5% |
About Dr. Kathy Ta, M.D
Dr. Kathy Ta, M.D is a Retina Specialist healthcare provider based in Metairie, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/13/2011. The National Provider Identifier (NPI) number assigned to this provider is 1457646937.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kathy Ta, M.D has received a total of $2,693 in payments from pharmaceutical and medical device companies, with $352.43 received in 2024. These payments were reported across 83 transactions from 17 companies. The most common payment nature is "Food and Beverage" ($2,600).
As a Medicare-enrolled provider, Ta has provided services to 6,294 Medicare beneficiaries, totaling 14,660 services with total Medicare billing of $1.7M. Data is available for 4 years (2020–2023), covering 48 distinct procedure/service records.
Ad
Practice Information
- Specialty Retina Specialist
- Other Specialties Ophthalmology
- Location Metairie, LA
- Active Since 06/13/2011
- Last Updated 10/08/2025
- Taxonomy Code 207WX0107X
- Entity Type Individual
- NPI Number 1457646937
Products in Payments
- OZURDEX (Drug) $847.61
- EYLEA (Biological) $415.05
- YUTIQ (Drug) $244.84
- DEXYCU (Drug) $155.86
- VABYSMO (Drug) $149.22
- ACTHAR (Biological) $127.07
- Vabysmo (Drug) $95.89
- EYLEA AFLIBERCEPT INJECTION (Biological) $84.21
- XIPERE (Drug) $65.63
- BROLUCIZUMAB (Drug) $55.96
- Iluvien (Drug) $48.13
- Izervay (Drug) $45.51
- EYLEA HD (Biological) $32.30
- BEOVU (Drug) $30.34
- Daraprim (Drug) $28.80
- Cimerli (Biological) $26.02
- IHEEZO (Drug) $20.30
- Syfovre (Drug) $18.53
- BROMSITE (Drug) $15.13
- ILUVIEN (Drug) $14.65
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.